RecruitingPhase 1NCT06192888

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Pilot Study of Glofitamab and Lenalidomide in Patients With Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With a BTK Inhibitor

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

39 participants

Start Date

Jan 8, 2024

Study Type

INTERVENTIONAL

Conditions

Mantle Cell Lymphoma MCL

Summary

The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of glofitamab (a bispecific antibody that helps the immune system find cancer cells) and lenalidomide (an oral immune-modulating drug) for people with mantle cell lymphoma that has come back or stopped responding to prior treatments. **You may be eligible if...** - You are 18 or older - You have mantle cell lymphoma that has relapsed or is refractory to prior treatment (confirmed by biopsy) - If your prior treatment included anti-CD20 therapy, your tumor must still express CD20 - Your general health (ECOG 0–2) and organ function meet study requirements - You can provide tumor tissue for testing **You may NOT be eligible if...** - You have active CNS (brain or spinal fluid) involvement by lymphoma - You have uncontrolled heart, liver, or kidney disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGlofitamab

IV Glofitamab

DRUGObinutuzumab

IV Obinutuzumab

DRUGLenalidomide

Oral Lenalidomide

Locations(10)

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States

Washington University (Data Collection Only)

St Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Limited protocol activities)

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, United States

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)

Commack, New York, United States

Memorial Sloan Kettering Westchester (Limited protocol activities)

Harrison, New York, United States

Memorial Sloan Kettering Nassau (All protocol activities)

Rockville Centre, New York, United States

Dana Farber Cancer Institute (Data Collection and Specimen Analysis)

Boston, Massachusetts, United States

Mayo Clinic (Data Collection Only)

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06192888

Related Trials

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

NCT062634911 location

A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

NCT052456561 location

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996148 locations

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716127 locations

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

NCT068390531 location